查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863477

肿瘤精准医疗市场（依治疗方法、癌症类型、技术、生物标记类型和最终用户划分）－2025-2032年全球预测

Oncology Precision Medicine Market by Therapy Type, Cancer Type, Technology, Biomarker Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肿瘤精准医疗市场将成长至 166.4 亿美元，复合年增长率为 10.16%。

关键市场统计数据
基准年 2024 76.7亿美元
预计年份：2025年 84.3亿美元
预测年份 2032 166.4亿美元
复合年增长率 (%) 10.16%

一份策略性入门指南，阐述诊断创新、治疗方法进展和数据整合如何重新定义精准肿瘤学的临床路径和商业性模式。

精准肿瘤学正处于一个转折点，治疗方法、诊断技术和数据分析的进步正在融合，重塑临床决策和商业策略。免疫疗法、标靶药物和分子诊断的最新创新，正将重点从「一刀切」的治疗模式转向精准的患者照护路径，这需要新的证据生成模型，以及临床、监管和支付方等相关人员之间更紧密的合作。

本导言概述了变革的关键驱动因素，概述了对开发商和供应商的实际意义，并为后续章节提供了框架，这些章节将探讨结构性转变、与关税相关的供应链风险以及特定领域的动态。相关人员面临日益复杂的局面：多重检测和次世代定序结果可即时指导治疗方案的选择，伴随诊断组合在临床试验设计和产品定位中也变得越来越重要。

此外，随着医疗服务日益分散化，诊断实验室和门诊机构也开始采用以往仅限于三级医疗中心的技术。对整合营运规划、跨职能协作和资料互通性的投资，对于从概念验证过渡到可扩展的实施至关重要。后续分析揭示了组织重点关注哪些领域最有可能带来持续的临床和商业性优势。

治疗方法的进步、诊断多重化以及支付方期望的改变，都要求在癌症治疗的开发和实施过程中采取综合策略方法。

精准癌症医学领域正经历着一场变革性的转变，其驱动力包括科技的成熟、监管环境的演变以及相关人员期望的改变。免疫疗法，例如CAR-T细胞疗法和查核点抑制剂，正从新兴疗法发展成为治疗流程中的关键组成部分，重新​​定义了骨髓恶性肿瘤和某些固态肿瘤的治疗结果。同时，以单株抗体和小分子抑制剂形式递送的标靶治疗，透过不断改进的标靶检验和持续发展的抗药性管理策略，也不断提高治疗效果。

诊断技术已从单分析物检测发展到多重检测平台。虽然免疫组织化学和萤光杂合反应仍然是基础技术，但聚合酵素链锁反应(PCR) 检测和次世代定序技术能够以临床可操作的深度进行广泛的基因组分析。诊断技术的扩展有助于对常见癌症类型进行更精确的分层，使临床医生能够更有把握地根据肿瘤生物学特征制定治疗方法。

在商业方面，支付者和医疗保健系统要求提供更有力的临床效用和真实世界疗效证据，迫使申办方设计适应性试验框架和核准后证据计画。诊断提供者和药物研发商之间的合作日益增多，联合开发和打包报销模式也变得越来越普遍。总而言之，这些变化凸显了製定整合式临床开发策略的重要性，该策略需预见监管预期和医疗服务体系的限制。

评估新关税政策对精准肿瘤学领域供应链、实验室运作和临床专案韧性的营运和策略影响

2025年实施的新关税政策增加了精准肿瘤学生态系统的运作复杂性，影响了试剂、仪器组件和生物製品生产的供应链。单株抗体、细胞治疗材料和定序平台的生产商面临某些进口原料和仪器组件更高的到岸成本，迫使他们重新评估筹资策略和库存管理实务。

这些与关税相关的压力也对临床开发和实验室运作产生了连锁反应。依赖进口耗材的诊断实验室面临更长的采购前置作业时间和更大的成本波动，这可能会扰乱检测标准化和实验室认证的进度。进行全球临床试验的申办者必须考虑区域成本差异和临床实验药物供应可能中断的情况，这会影响研究中心的选择和研究物流。

为因应这项挑战，各组织正致力于供应商多元化，尽可能优先选择国内製造伙伴关係，并重新设计包装和运输方式，以减少对关税敏感品类的依赖。监理申报和品质管理系统必须包含供应商替换的紧急时应对计画，合约团队也正在与供应商协商更灵活的条款。儘管关税带来了巨大的执行风险，但它也加速了对区域分散式製造能力的投资，并推动建立强大的供应链网络，以确保治疗和诊断产品的持续供应。

基于细分的治疗类别、癌症类型、诊断技术、生物标记分类和最终用户采用情况的洞察，可指导优先排序。

基于细緻细分的分析突显了价值创造和营运重点领域。就治疗方法类型而言，荷尔蒙疗法仍然是多种治疗途径的基础；免疫疗法涵盖了CAR-T细胞疗法等细胞疗法和全身性查核点抑制剂；标靶治疗涵盖了单株抗体和小分子抑制剂。每种治疗类别都有其独特的研发、生产和商业化考量，这些都会影响跨职能规划。

按癌症类型细分，突显了每种疾病领域独特的临床和诊断需求。乳癌、大肠癌、肺癌、黑色素瘤和摄护腺癌各自拥有独特的生物标记谱、不同的标准治疗方案，以及支付者对先进诊断和联合治疗的报销意愿。针对每种肿瘤类型的自然病程和治疗模式，制定相应的临床证据策略，可以提高诊断和治疗方案组合的有效性。

技术细分将支撑现代诊断的调查方法进行分类，包括萤光原位杂合反应、免疫组织化学、次世代定序和聚合酵素链锁反应。每种技术在灵敏度、通量、週转时间和操作规模方面各有优劣，决定了其实际应用场景。依生物标记类型细分，涵盖表观遗传学、遗传学和蛋白质检测，可进一步细化检测对治疗决策和监管路径的影响程度。

按最终用户进行细分有助于明确产品采纳和商业化路径。门诊中心、诊所、诊断实验室和医院的资金资源、工作流程整合能力和报销编码方式各不相同。使产品设计和服务模式与这些最终用户的营运实际情况相匹配，有助于加快产品采纳和更顺利地实施。总而言之，这种多层次细分方法有助于更精准地确定投资优先顺序、产生证据并优化产品上市时间。

区域比较分析突显了关键区域在采纳率、报销和基础设施方面的差异如何导致精准癌症治疗策略的差异化。

区域趋势正在影响精准癌症治疗生态系统的应用模式和策略重点。在美洲，创新中心和完善的临床基础设施支持先进治疗方法和全面基因组分析的快速应用，而支付方环境和报销途径的差异则要求制定针对国家和地方市场的循证方案和支付方参与策略。

欧洲、中东和非洲地区（EMEA）监管环境的差异以及获得专科医疗服务的不平等，正在影响诊断技术和新疗法的引入。欧洲部分地区的集中式卫生技术评估（HTA）机制着重于疗效比较和成本效益，而中东某些市场则正在为先进的细胞疗法和精准诊断奠定基础。在非洲部分地区，有限的检测基础设施和薄弱的供应链需要专门的模式来实现分散式检查和可持续的试剂供应。

亚太地区拥有成熟的大都会圈和快速发展的医疗保健体系。多个市场正在大力投资高通量定序技术和本土生物製药生产，这为区域供应伙伴关係和本地化临床开发创造了机会。同时，监管协调和不断变化的报销标准要求制定灵活的准入策略，以加快患者获得治疗，同时满足当地的循证医学要求。在所有地区，相关人员必须将全球产品策略与当地细緻入微的营运和监管实际情况相协调。

策略联盟、平台投资以及关键参与者之间的垂直整合如何重塑精准癌症治疗领域的竞争格局和价值获取方式

治疗、诊断和综合服务领域的领导企业正透过策略联盟、平台投资和垂直整合重塑竞争动态。生物製药企业正日益与诊断开发商合作，共同设计伴随检测和并行证据生成项目，以支持监管申报和与支付方的沟通。诊断实验室和设备供应商正投资于自动化和数位化报告，以扩大高复杂度检测的规模，同时提高检测的可重复性和周转时间。

为了满足日益增长的复杂治疗方法需求，供应链合作伙伴和契约製造正在扩展其细胞疗法支援服务以及生物製药填充和最终包装能力。科技公司正在采用云端基础的分析和机器学习技术，以提高变异解读的准确性，并为临床医生开发决策支援工具，将定序结果转化为可操作的见解。这些发展正在影响策略联盟、併购活动以及优选供应商网路的形成。

能够证明其在整个生态系统中端到端地整合了强大的分析有效性、临床效用和切实可行的实施支持价值的公司，将更有利于在医疗服务提供者网络中获得更广泛的认可，并与支付方实现有效的合作。在中短期内，卓越的生产运作、对监管法规的深刻理解以及提供真实世界证据的能力，将使行业领导者脱颖而出，区别于追随者。

为整合诊断技术开发、供应链韧性和实证实践，以加速其应用和获得支付方认可，提出切实可行且影响深远的建议。

行业领导者应采取果断措施，协调临床开发、诊断策略和商业性化实施，确保治疗进展能够转化为持续的患者获益和永续的商业成果。优先事项包括将伴随诊断的开发更早纳入治疗生命週期，这将降低监管风险，并为支付方和医疗服务提供者创造更清晰的价值提案。领导者应透过供应商多元化、尽可能采用双重采购以及对区域製造能力进行策略性投资来增强供应链韧性。

在营运方面，各机构必须投资于可互通的资料平台和证据生成框架，以支持快速累积真实世界的结果。加强与诊断实验室和医疗服务机构的合作将加速技术的应用，尤其是在明确定义实施流程和报销途径的情况下。同时，商业部门应针对每种癌症类型，建构反映其独特临床背景和所采用诊断技术的客製化卫生经济学叙事。

最后，建构整合监管、临床、商业和供应链决策的跨职能管治，可降低实施风险，并改善上市前后各项活动的协调。透过优先进行这些工作，领导者将更有能力在应对监管复杂性、支付方审查和营运中断的同时，实现患者照护的可衡量改善。

采用稳健的多方法调查方法，结合专家访谈、监管和临床证据审查以及情境分析，以支持实用见解。

这项综合研究采用多方面方法，旨在捕捉精准肿瘤学领域的技术、临床、监管和营运发展。透过对临床意见领袖、实验室主任和供应链高管的访谈，我们获得了关于检测应用和治疗部署实际操作情况的定性见解。这些一线观点与已发布的监管决策、同行评审的临床文献和技术产品文件进行交叉验证，以确保其符合最新的临床和技术标准。

对诊断工作流程、技术应用案例和支付方政策声明的二次分析，指导了部署限制和报销驱动因素的评估。情境分析用于对供应链脆弱性进行压力测试，并识别各组织目前实施的切实可行的缓解措施。我们的调查方法强调资讯来源的透明度和对定性资料的谨慎解读，着重于可观察的趋势和已记录的政策变化，而非推测性的预测。

在整个研究过程中，我们力求从多个相关人员取得证据，并在缺乏共识之处探讨不同观点。这种混合方法框架旨在为决策者提供平衡且切实可行的策略和营运选择视角，这些选择将影响未来精准癌症治疗的发展方向。

策略结论强调了诊断、治疗研发和稳健运作的整合，以确保患者疗效的持续性和商业性成功。

总之，精准肿瘤学正迈入一个以整合诊断、特异性治疗方法策略以及对真实世界证据日益增长的需求为特征的新时代。免疫疗法、标靶治疗和先进诊断平台之间的相互作用正迫使相关人员重新思考研发范式、商业模式和营运基础设施。那些能够将伴随诊断研发与治疗方案同步推进、建立稳健的供应链网络并投资于可互通数据系统的机构，将更有能力将科学进步转化为持续的临床获益。

关税相关的供应风险和区域间准入环境的差异凸显了製定灵活、本地化策略的必要性。透过优先考虑跨职能管治和儘早与支付方接洽，申办方和服务供应商可以降低推广障碍，加速创新成果转化为常规实践。将严谨的科学研究与切实可行的营运设计相结合，高效、可持续地将有前景的治疗方法提供给合适的患者，将是未来成功的关键。

综上所述，这些结论为希望清晰、有目标地驾驭不断发展的精准癌症治疗生态系统的相关人员提供了策略基础。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将液态生物检体检测整合到临床工作流程中，用于肿瘤的早期检测和监测
  • 利用人工智慧驱动的基因组数据分析平台实现肿瘤免疫疗法的个人化治疗
  • 癌症类型无关药物核准的出现：针对特定基因突变，适用于多种癌症类型
  • 整合多体学学分析以优化患者分层和治疗选择。
  • 开发靶向新型肿瘤抗原且具有更高特异性的抗体药物复合体
  • 利用新一代工程技术拓展CAR-T细胞疗法在固体癌的应用
  • 利用电子健康记录中的真实世界证据改进精准医疗策略

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 肿瘤精准医疗市场（依治疗方法）

  • 荷尔蒙疗法
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
  • 标靶治疗
    • 单株抗体
    • 小分子抑制剂

第九章 按癌症类型分類的肿瘤精准医疗市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 黑色素瘤
  • 摄护腺癌

10. 按技术分類的肿瘤精准医疗市场

  • FISH
  • 免疫组织化学（IHC）
  • 次世代定序
  • PCR

第十一章：以生物标记类型分類的肿瘤精准医疗市场

  • 表观遗传学检测
  • 基因检测
  • 蛋白质检测

第十二章：依最终用户分類的肿瘤精准医疗市场

  • 门诊治疗中心
  • 诊所
  • 诊断实验室
  • 医院

第十三章：肿瘤精准医疗市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肿瘤精准医疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国肿瘤精准医疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.
    • Illumina, Inc.
    • QIAGEN NV
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Guardant Health, Inc.
Product Code: MRR-5C6F41F5B030

The Oncology Precision Medicine Market is projected to grow by USD 16.64 billion at a CAGR of 10.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.67 billion
Estimated Year [2025] USD 8.43 billion
Forecast Year [2032] USD 16.64 billion
CAGR (%) 10.16%

A strategic primer introducing how diagnostic innovation, therapeutic evolution, and data integration are jointly redefining precision oncology clinical pathways and commercial approaches

Precision oncology stands at an inflection point as converging advances in therapeutics, diagnostics, and data analytics reshape clinical decision making and commercial strategy. Recent innovations in immunotherapy modalities, targeted agents, and molecular diagnostics have shifted the emphasis from one-size-fits-all approaches to finely stratified patient care pathways, demanding new evidence-generation models and closer alignment across clinical, regulatory, and payer stakeholders.

This introduction synthesizes the principal drivers of change, outlines the practical implications for developers and providers, and frames the subsequent sections that probe structural shifts, tariff-related supply chain risks, and segmentation-specific dynamics. Stakeholders face accelerating complexity: multiplex assays and next-generation sequencing outputs are informing therapy selection in real time, and companion diagnostic pairing is increasingly integral to clinical trial design and product positioning.

Moreover, as care delivery becomes more decentralized, diagnostic laboratories and ambulatory settings are adopting technologies that were once confined to tertiary centers. Transitioning from proof-of-concept to scalable implementation requires integrated operational plans, cross-functional collaboration, and investment in data interoperability. The subsequent analysis highlights where organizational focus is most likely to yield durable clinical and commercial advantage.

How converging therapeutic advances, diagnostic multiplexing, and evolving payer expectations are forcing integrated strategic approaches across oncology development and delivery

The landscape of precision oncology is undergoing transformative shifts driven by technological maturation, regulatory evolution, and changing stakeholder expectations. Immunotherapies such as CAR T-cell interventions and checkpoint inhibitors have moved from novelty to essential components of treatment algorithms, redefining outcomes in hematologic malignancies and selected solid tumors. Concurrently, targeted therapies delivered as monoclonal antibodies or small molecule inhibitors continue to refine therapeutic windows through improved target validation and resistance management strategies.

Diagnostics have evolved from single-analyte tests to multiplexed platforms; immunohistochemistry and fluorescence in situ hybridization remain foundational, while polymerase chain reaction assays and next-generation sequencing now enable broader genomic profiling at clinically actionable depth. This diagnostic breadth supports more precise stratification across common cancer types, allowing clinicians to match interventions to tumor biology with greater confidence.

Commercially, payers and health systems are demanding stronger evidence of clinical utility and real-world benefit, prompting sponsors to design adaptive trial frameworks and post-approval evidence programs. Partnerships between diagnostics providers and pharmaceutical developers are expanding, with co-development and bundled reimbursement models gaining traction. Taken together, these shifts elevate the importance of integrated clinical development strategies that anticipate regulatory expectations and delivery system constraints.

Assessing the operational and strategic consequences of new tariff policies on supply chains, laboratory operations, and clinical program resilience across precision oncology

The introduction of new tariff policies in 2025 has introduced additional layers of operational complexity across the precision oncology ecosystem, affecting supply chains for reagents, instrument components, and biologic production inputs. Manufacturers of monoclonal antibodies, cell-therapy materials, and sequencing platforms face higher landed costs for certain imported raw materials and instrument subassemblies, prompting reassessments of sourcing strategies and inventory practices.

These tariff-related pressures have ripple effects through clinical development and laboratory operations. Diagnostic laboratories reliant on imported consumables may encounter longer procurement lead times and greater cost volatility, which can complicate assay standardization and laboratory accreditation timelines. Clinical trial sponsors operating global studies must now account for variable local costs and potential disruptions to investigational product supply, influencing site selection and trial logistics.

In response, organizations are intensifying efforts to diversify supplier bases, prioritize domestic manufacturing partnerships where feasible, and redesign packaging and shipment practices to reduce exposure to tariff-sensitive categories. Regulatory submissions and quality programs must incorporate contingency planning for supplier substitutions, and contracting teams are negotiating more flexible terms with vendors. While tariffs present material execution risks, they are also accelerating investments in regionalized manufacturing capacity and robust supply network mapping to preserve continuity in both therapeutic and diagnostic delivery.

Segmentation-driven insights that delineate therapeutic categories, cancer types, diagnostic technologies, biomarker classes, and end-user deployment realities to guide prioritization

A careful segmentation-driven lens clarifies where value is created and where operational attention is required. When considering therapy type, hormonal treatments continue to anchor several care pathways, immunotherapies encompass both cellular approaches such as CAR T-cell therapy and systemic checkpoint inhibitors, and targeted therapy spans monoclonal antibodies as well as small molecule inhibitors; each therapeutic category carries distinct development, manufacturing, and commercialization considerations that influence cross-functional planning.

Cancer-type segmentation highlights the divergent clinical and diagnostic needs across disease areas: breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer each present unique biomarker landscapes, differing standard-of-care backdrops, and variable payer willingness to reimburse advanced diagnostics and combination regimens. Tailoring clinical evidence strategies to the natural history and treatment paradigms of each tumor type enhances the relevance of diagnostic-therapeutic pairings.

Technology segmentation separates the methodological approaches that underpin contemporary diagnostics, including fluorescence in situ hybridization, immunohistochemistry, next-generation sequencing, and polymerase chain reaction. Each technology offers trade-offs across sensitivity, throughput, turnaround time, and operational footprint, influencing which settings can realistically adopt them. Biomarker-type segmentation-covering epigenetic testing, genetic testing, and protein testing-further refines where assays will impact treatment decisions and regulatory pathways.

End-user segmentation clarifies deployment and commercialization pathways: ambulatory care centers, clinics, diagnostic laboratories, and hospitals differ in capital capacity, workflow integration capability, and reimbursement coding practices. Aligning product design and service models to the operational realities of these end users supports faster adoption and smoother implementation. Collectively, this layered segmentation approach supports more precise prioritization of investment, evidence generation, and go-to-market sequencing.

Comparative regional analysis highlighting how adoption, reimbursement, and infrastructure differences across major geographies drive differentiated precision oncology strategies

Regional dynamics are shaping both adoption patterns and strategic priorities across the precision oncology ecosystem. In the Americas, innovation hubs and extensive clinical infrastructure support rapid uptake of advanced therapeutics and comprehensive genomic profiling, yet divergent payer environments and reimbursement pathways require targeted evidence planning and payer engagement strategies tailored to national and subnational markets.

Within Europe, the Middle East & Africa, heterogeneous regulatory landscapes and variable access to specialized care influence how diagnostics and novel therapies are introduced. Centralized health technology assessment mechanisms in parts of Europe emphasize comparative effectiveness and cost-effectiveness, while select markets in the Middle East are building capacity for advanced cell therapies and precision diagnostics. In parts of Africa, constrained laboratory infrastructure and supply chain fragility necessitate tailored models for decentralized testing and durable reagent supply.

The Asia-Pacific region presents a spectrum of mature metropolitan centers alongside rapidly developing healthcare systems. High-throughput sequencing adoption and investments in domestic biologics manufacturing are notable in several markets, creating opportunities for regional supply partnerships and localized clinical development. At the same time, regulatory harmonization and variable reimbursement criteria require flexible access strategies that can accelerate patient access while meeting local evidence requirements. Across regions, stakeholders must reconcile global product strategies with nuanced local operational and regulatory realities.

How strategic alliances, platform investments, and vertical integration among leading players are reshaping competitive dynamics and value capture in precision oncology

Leading organizations in therapeutics, diagnostics, and integrated service provision are reshaping competitive dynamics through strategic alliances, platform investments, and vertical integration. Biopharmaceutical sponsors are increasingly collaborating with diagnostic developers to co-design companion assays and parallel evidence-generation programs that support regulatory filings and payer conversations. Diagnostic laboratories and instrument providers are investing in automation and digital reporting to scale high-complexity testing while improving reproducibility and turnaround times.

Supply chain partners and contract manufacturers are expanding capabilities in cell-therapy support services and biologics fill-finish operations to meet rising demand for complex modalities. Technology companies are deploying cloud-based analytics and machine learning to enhance variant interpretation and to create clinician-facing decision support tools that translate sequencing outputs into actionable insights. These moves are influencing strategic partnerships, M&A activity, and the formation of preferred supplier networks.

Across the ecosystem, firms that can demonstrate end-to-end value-linking robust analytical validity, clinical utility, and practical implementation support-are positioned to secure stronger adoption in provider networks and to engage more effectively with payers. Operational excellence in manufacturing, regulatory acumen, and the capacity to deliver real-world evidence will distinguish leaders from followers in the near to medium term.

Practical and high-impact recommendations for leaders to integrate diagnostic-development, supply resilience, and evidence generation to accelerate adoption and payer acceptance

Industry leaders should take decisive steps to align clinical development, diagnostic strategy, and commercial implementation so that therapeutic advances translate into durable patient benefit and sustainable business outcomes. Priorities include embedding companion diagnostic development early in the therapeutic lifecycle to de-risk regulatory pathways and to create clearer value propositions for payers and providers. Leaders should reinforce supply chain resilience through supplier diversification, dual sourcing where feasible, and strategic investments in regional manufacturing capabilities.

Operationally, organizations must invest in interoperable data platforms and evidence-generation frameworks that support rapid accumulation of real-world outcomes. Strengthening collaborations with diagnostic laboratories and care delivery settings will accelerate adoption, particularly when implementation workflows and reimbursement pathways are clearly addressed. In parallel, commercial teams should develop tailored health-economic narratives that reflect the specific clinical contexts of each cancer type and the diagnostic technologies employed.

Finally, fostering cross-functional governance that integrates regulatory, clinical, commercial, and supply chain decision-making will reduce time-to-adoption risks and improve alignment across launch and post-launch activities. By prioritizing these actions, leaders will be better positioned to navigate regulatory complexity, payer scrutiny, and operational disruption while delivering measurable improvements in patient care.

Robust multi-method research methodology combining expert interviews, regulatory and clinical evidence review, and scenario analysis to underpin actionable insights

The research behind this synthesis integrates a multi-method approach to capture technological, clinical, regulatory, and operational developments across precision oncology. Primary interviews with clinical thought leaders, laboratory directors, and supply chain executives provided qualitative insights into the operational realities of assay implementation and therapeutic deployment. These firsthand perspectives were triangulated with public regulatory decisions, peer-reviewed clinical literature, and technical product documentation to ensure alignment with the latest clinical and technological standards.

Secondary analysis of diagnostic workflows, technology adoption case studies, and payer policy statements informed the assessment of deployment constraints and reimbursement drivers. Scenario analysis was applied to stress-test supply chain vulnerabilities and to identify pragmatic mitigation steps that organizations are currently implementing. The methodology emphasizes transparency in source attribution and conservative interpretation of qualitative inputs, focusing on observable trends and documented policy shifts rather than speculative projections.

Throughout the research process, efforts were made to corroborate findings across multiple stakeholders and to surface divergent perspectives where consensus is lacking. This mixed-methods framework is intended to provide decision-makers with a balanced, actionable view of the strategic and operational choices that will shape precision oncology over the near term.

Synthesis of strategic conclusions emphasizing integration of diagnostics, therapy development, and resilient operations to secure durable patient and commercial outcomes

In conclusion, precision oncology is transitioning into an era defined by integrated diagnostics, modality-specific therapeutic strategies, and heightened expectations for real-world evidence. The interplay between immunotherapies, targeted agents, and advanced diagnostic platforms is prompting stakeholders to rethink development paradigms, commercial models, and operational infrastructure. Organizations that synchronize companion diagnostic development with therapeutic programs, build resilient supply networks, and invest in interoperable data systems will be better equipped to translate scientific advances into consistent clinical benefit.

Tariff-related supply risks and varied regional access environments underscore the need for flexible, regionally informed strategies. By prioritizing cross-functional governance and early payer engagement, sponsors and service providers can mitigate adoption barriers and accelerate the translation of innovations into standard practice. The path forward favors those who combine scientific rigor with pragmatic operational design, ensuring that promising therapies reach the right patients efficiently and sustainably.

Taken together, these conclusions provide a strategic foundation for stakeholders seeking to navigate the evolving precision oncology ecosystem with clarity and purpose.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy assays into clinical workflows for early tumor detection and monitoring
  • 5.2. Adoption of AI-driven genomic data analysis platforms to personalize immuno-oncology therapies
  • 5.3. Emergence of tumor-agnostic drug approvals targeting specific genetic alterations across cancer types
  • 5.4. Integration of multiomics profiling for more precise patient stratification and therapy selection
  • 5.5. Development of antibody-drug conjugates targeting novel tumor antigens with enhanced specificity
  • 5.6. Expansion of CAR-T cell therapies into solid tumors through next-generation engineering approaches
  • 5.7. Utilization of real-world evidence from electronic health records to refine precision medicine strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Precision Medicine Market, by Therapy Type

  • 8.1. Hormonal Therapy
  • 8.2. Immunotherapy
    • 8.2.1. CAR T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
  • 8.3. Targeted Therapy
    • 8.3.1. Monoclonal Antibodies
    • 8.3.2. Small Molecule Inhibitors

9. Oncology Precision Medicine Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Melanoma
  • 9.5. Prostate Cancer

10. Oncology Precision Medicine Market, by Technology

  • 10.1. FISH
  • 10.2. IHC
  • 10.3. Next Generation Sequencing
  • 10.4. PCR

11. Oncology Precision Medicine Market, by Biomarker Type

  • 11.1. Epigenetic Testing
  • 11.2. Genetic Testing
  • 11.3. Protein Testing

12. Oncology Precision Medicine Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals

13. Oncology Precision Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oncology Precision Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oncology Precision Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. F. Hoffmann-La Roche Ltd.
    • 16.3.3. Illumina, Inc.
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Danaher Corporation
    • 16.3.6. Agilent Technologies, Inc.
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Guardant Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ONC